An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Patients With Metastatic Renal Cell Carcinoma That is Progressive Following or During Immunotherapy
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the rate of objective response (the best response of Complete Response (CR), Partial Response (PR)).
Up to 6 months
William McCulloch, MB, FRCP
Gloucester Pharmaceuticals Inc.
United States: Food and Drug Administration
|City of Hope National Medical Center||Los Angeles, California 91010|
|Seattle Cancer Care Alliance||Seattle, Washington 98109|
|University of Chicago||Chicago, Illinois 60637|